Sort
82,697 grants matching “vaccine development”
Project 1
$1,264,760Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2021 · AI
Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERS
$1,264,670Peter Jahrling · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials
$1,264,663Rafick-Pierre Sekaly · Case Western Reserve University · R01 · FY2016 · AI
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,264,618Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Testing of Blood Samples for Immune Response and Vaccine Research
$1,263,878Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Testing of Blood Samples for Immune Response and Vaccine Research
$1,263,878Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Immune correlates of protection
$1,263,878Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Immune correlates of protection
$1,263,877Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Immune correlates of protection
$1,263,877Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Basic Research Support for the CCR
$1,263,819Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,263,633Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION
$1,263,565Jeffrey Nordstrom · Macrogenics, Inc. · N01 · FY2018 · AI
Fc effector function in bNAbs
$1,263,378Jeffrey Victor Ravetch · California Institute Of Technology · P01 · FY2016 · AI
Antigen Processing And Presentation In The Intestine
$1,263,120Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Localized mHealth approach to boosting COVID-19 testing and vaccine literacy, access, and uptake among women with criminal legal system involvement
$1,262,938Megha Ramaswamy · University Of Kansas Medical Center · U01 · FY2022 · MD
Gut Homing Cells in SIV infection
$1,262,680Aftab A. Ansari · Emory University · R01 · FY2013 · AI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
$1,262,646Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · AI
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$1,262,498Elias Sayour · University Of Florida · R01 · FY2022 · FD
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,261,924Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$1,261,890University Of Alabama At Birmingham · U01 · FY2003 · AI
Malaria Transmission Blocking Vaccine Discovery
$1,261,623Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS
$1,261,168Margaret Mentink-Kane · Biomedical Research Institute · N01 · FY2018 · AI
Computational biology scientific research support component
$1,261,104Thomas B Kepler · Duke University · UM1 · FY2013 · AI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma
$1,260,778Smriti Mehra · Texas Biomedical Research Institute · R01 · FY2022 · AI
Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine
$1,260,556Christopher Fox · Access To Advanced Health Institute · N01 · FY2024 · AI